Baseline factors independently associated with a higher incidence of sustained visual acuity loss were the presence of nonfoveal GA ( odds ratio [ OR ] , 2.86 ; 95 % CI , 1.35-6 .08 ; P = .006 ) , larger area of choroidal neovascularization ( OR for a > 4-disc area vs 1-disc area , 3.91 ; 95 % CI , 1.70-9 .03 ; P = .007 ) , and bevacizumab treatment ( OR , 1.83 ; 95 % CI , 1.07-3 .14 ; P = .03 ) .